1.. Introduction {#s0001}
================

Malaria remains the main cause of death all over the world and we are unable to reverse this sad morbidity statistic. Indeed, during the year 2015, 212 million cases of malaria and 429 thousand death cases were reported by the WHO[@CIT0001]. *Plasmodium falciparum* (*Pf*), the most virulent causative agent of malaria, is developing resistance rapidly so that the future of the Artemisinin Combined Therapy (ACT, available since 2006) is compromised[@CIT0002]. For almost a decade the development of novel antimalarials concerned mainly ACT, as recently exemplified by introduction of the combination of artemether and lumefantrine referred to as *novamether* [@CIT0003]. Luckily, this alarming dark picture has been illuminated by the reported new antimalarial candidates[@CIT0004]. Relatively low level of structural knowledge of novel and validated pharmacological targets of the *Pf* on one side and the lack of inhibition pharmacophores on the other, remain the drawbacks of antimalarial drug design (ADD) and development. One of the recent ADD strategies was to design hybrids molecules containing artemisinin (ART) or other antimalarial combined with another structural fragment[@CIT0006]. Falcipains have drawn the attention of ADD due to their important role in the haemoglobin degradation (along with plasmepsins) while their inhibition is lethal to the *Pf* [@CIT0009]. Lactone--chalcone and isatin--chalcone (HLCIC) hybrid molecules have been mentioned in this context, their experimental FP-2 inhibitory activities were reported[@CIT0012]. They essentially target the bipartite motifs of falcipain-2 (FP-2) and falcipain-3 (FP-3), the papain-family cysteine proteases of *Pf*, which are involved in the degradation of host's haemoglobin within the food vacuole during the blood-stage of the parasite[@CIT0013] ^,^ [@CIT0014]. Due to their specific features, falcipains represent promising targets for the development of next-generation antimalarials[@CIT0010] ^,^ [@CIT0014].

In this work, we design new analogues of HLCIC starting from a series of 15 known HLCIC hybrids with determined experimental inhibition potencies (*IC* ~50~ ^exp^), which were used as a training set[@CIT0012]. We build on our design and new analogue activity prediction relies on a reliable descriptor, namely standard Gibbs free energy (GFE) of enzyme:inhibitor (E:I) complex formation (Δ*G* ~com~), quantitative structure--activity relationships (QSAR), 3D structural model of the FP-2 and analysis of the inhibitor--enzyme interactions. Relative changes in the GFE of E:I complex formation were computed in order to build a linear regression QSAR model utilising the published *IC* ~50~ ^exp^ [@CIT0012]. Each complex was carefully built by *in situ* modification of the reference crystal structure of FP-2 (3BPF)[@CIT0015] in complex with epoxysuccinate E64 ([Figure 1](#F0001){ref-type="fig"}). The 3D models of inhibitors bound to FP-2, QSAR and pharmacophore (PH4) models derived for the training set compounds provided the necessary structural information needed to improve inhibitor interactions at pockets S1, S2, and S3 of the FP-2 active site. Screening of designed virtual library (VL) of analogues by the PH4 led to the identification of potent HLCIC, which are predicted to be hundreds of times more potent than the best training set inhibitor HLCIC1 (*IC* ~50~ ^exp^ = 6.8 µM).

![(a) Molecular structure of epoxysuccinate E64 with indicated P1, P2, and P3 positions. (b) 3D depiction of E64 interactions with the FP-2 active site residues involving residues that occupy S1, S2, and S3 pockets of the active site[@CIT0015].](IENZ_A_1564288_F0001_C){#F0001}

2.. Materials and methods {#s0002}
=========================

The methodology of computer-assisted molecular design based on 3D models of E:I complexes and QSAR analysis of a training set of known inhibitors has been successfully applied to optimisation of antiviral, antibacterial, and anti-protozoan compounds including peptidomimetic, hydroxynaphthoic, thymidine, triclosan, pyrrolidine carboxamide derivatives, peptidic, and ART hybrids inhibitors[@CIT0008] ^,^ [@CIT0016]. The workflow shown in [Figure 2](#F0002){ref-type="fig"} describes the series of steps of virtual design of novel HLCIC analogues.

![Workflow describing the multistep approach to virtually designed novel HLCIC analogues with higher predicted potencies against the FP-2 of *Pf*.](IENZ_A_1564288_F0002_C){#F0002}

2.1.. Training sets {#s0003}
-------------------

The chemical structures of the training set compounds comprising 15 HLCIC hybrids and their experimental biological activities (IC~50~ ^exp^ = 6.8--90 µM) are taken from the literature[@CIT0012]. The IC~50~ ^exp^ values of the HLCIC compounds cover a relatively wide concentration range, which is needed to build a reliable QSAR model.

2.2.. Model building and calculation of binding affinity {#s0004}
--------------------------------------------------------

Molecular modelling was carried out for the E:I (FP-2:HLCIC) complexes, the free enzyme FP-2, and the free HLCIC inhibitors starting from the high-resolution crystal structure of FP-2 co-crystallised with epoxysuccinate E64 inhibitor (*PDB* code 3BPF, resolution 2.9 Å) using Insight II molecular modelling program[@CIT0027]. Initially, all crystallographic waters were removed, then hydrogens were added to the residues of the FP-2 and FP-2:HLCIC complex with the protonisation/ionisation state corresponding to the pH of 7 keeping the N- and C-terminal groups neutral. Inhibitors were modelled from the 3BPF reference crystal structure by *in situ* modification of functional groups in the molecular scaffold of the endogenous E64 inhibitor. All rotatable bonds of the replacing fragments were subjected to an exhaustive conformational search coupled with a careful gradual energy-minimisation of the modified inhibitor and active-site residues of FP-2 located in the immediate vicinity (5 Å radius) in order to identify low-energy bound conformations of the modified inhibitors. The resulting low-energy structures of the E:I complexes were then carefully refined by energy-minimisation procedure of the entire complex to obtain stable structures of the binary FP-2:HLCIC complexes. The complete description of the computation of relative ligand binding affinity (ΔΔ*G* ~com~) is described in Ref. \[[@CIT0025]\]: $$\Delta\Delta G_{\text{com}} = \Delta G_{\text{com}}\left( I \right) - \Delta G_{\text{com}}\left( I_{\text{ref}} \right) = \Delta\Delta H_{\text{MM}} - \Delta\Delta TS_{\text{vib}} + \Delta\Delta G_{\text{sol}}$$

The ΔΔ*H* ~MM~ describes the relative enthalpic contribution to the GFE change corresponding to the intermolecular interactions in the E:I complex estimated by molecular mechanics (MM), ΔΔ*G* ~sol~, and ΔΔ*TS* ~vib~ represent the relative solvation and vibrational entropy contributions to the GFE of the E:I complex formation, respectively.

2.3.. Molecular mechanics {#s0005}
-------------------------

Modelling of the inhibitors and their complexes were carried out in all-atom representation using atomic parameters and charges of the class II consistent force field CFF91[@CIT0022]. A dielectric constant of 4 was used for all MM calculations in order to take into account the dielectric shielding effect in proteins. Minimisations of the E:I complexes, free E and I were carried out by relaxing the structures gradually, starting with added hydrogen atoms, continued with residue side chain heavy atoms and followed by the protein backbone relaxation. Geometry optimisations were performed using the sufficient number of steepest descent and conjugate gradient iterative cycles and average gradient convergence criterion of 0.01 kcal·mol^−1^·Å^−1^.

2.4.. Solvation GFE {#s0006}
-------------------

The electrostatic component of the solvation GFE, which includes also the effect of ionic strength of the solvent by solving the non-linear Poisson--Boltzmann equation[@CIT0028] ^,^ [@CIT0029] was computed by the DelPhi module of the Discovery Studio (DS 2.5)[@CIT0030]. The program represents the solvent by a continuous medium of high dielectric constant (*ε* ~ro~ = 80) and the solute as a charge distribution filling a low dielectric cavity (*ε* ~ri~ = 4) with boundaries linked to the solute's molecular surface. The program numerically solves for the molecular electrostatic potential and reaction field around the solute using finite difference method. DelPhi calculations were done on a (235 × 235 × 235) cubic lattice grid for the E:I complexes and free E and on a (65 × 65 × 65) grid for the free I. Full coulombic boundary conditions were employed. Two subsequent focusing steps led to a similar final resolution of about 0.3 Å per grid unit at 70% filling of the grid by the solute. Physiological ionic strength of 0.145 mol·dm^−3^, atomic partial charges and radii defined in the CFF force field parameter set[@CIT0030] and a probe sphere radius of 1.4 Å were used. The electrostatic component of the Poisson--Boltzmann solvation GFE was calculated as the reaction field energy[@CIT0021] ^,^ [@CIT0024] ^,^ [@CIT0029] ^,^ [@CIT0031] ^,^ [@CIT0032].

2.5.. Interaction energy {#s0007}
------------------------

The molecular mechanic interaction energy (*E* ~int~) calculation protocol available in DS 2.5[@CIT0030] was used to compute the non-bonded interactions (van der Walls and electrostatic interatomic potential terms) between two sets of atoms belonging either to the E or I in the E:I complexes. All pairs of interactions of the total enzyme--inhibitor interaction energy were evaluated using CFF force field parameters with a relative permittivity of 4[@CIT0030]. In particular, the breakdown of *E* ~int~ into contributions from individual active site residues allows a quantitative analysis, which permits identification of residues with the highest contribution to the ligand binding. It also helps with the identification of favourable structural modifications and suggests molecular moieties in the inhibitor structure which are primarily responsible for the biological activity of the compound[@CIT0022].

2.6.. 3D-QSAR pharmacophore generation {#s0008}
--------------------------------------

Pharmacophore (PH4) modelling assumes that a set of key structural features responsible for biological activity of the compound is recognised by the active site during receptor binding. In this work, the pharmacophore was prepared by the 3D-QSAR pharmacophore protocol of Catalyst HypoGen algorithm[@CIT0033] implemented in DS 2.5[@CIT0030]. Bound conformations of HLCIC inhibitors taken from the refined E:I complexes were considered for construction of the PH4. The top scoring pharmacophore hypothesis was prepared in three stages: constructive, subtractive, and optimisation step, from a set of most active HLCIC inhibitors. The inactive compounds served for the definition of excluded volume. During the PH4 generation, five features available in the HypoGen algorithm were used: hydrophobic aromatic (HYdAr), hydrophobic aliphatic (HYd), hydrogen-bond donor (HBD), acceptor (HBA), and ring aromatic (Ar) feature. Default values of the adjustable parameters were kept during the PH4 generation, except the uncertainty on the biological activity, which was reduced to 1.25 instead of 3. This adjustment modified the uncertainty interval of experimental activity from a wide span \[*IC* ~50~ ^exp^/3, 3×*IC* ~50~ ^exp^\] to a relatively narrow one\] \[4×*IC* ~50~ ^exp^/5, 5×*IC* ~50~ ^exp^/4\], due to accuracy and homogeneity of the measured activities originating from the same laboratory[@CIT0012]. The top ten pharmacophores were generated with the number of missing features set to zero. Finally, the best PH4 model was selected. Generally, a PH4 model, as the one described here, can be used to estimate the p*IC* ~50~ ^pre^ of new analogues on the basis of their mapping to its features. In this study, priority was given to PH4 based screening of ADME focused VL of HLCIC analogues.

2.7.. ADME-related properties {#s0009}
-----------------------------

Properties that determine the pharmacokinetics profile of a compound, besides octanol/water partitioning coefficient, aqueous solubility, blood/brain partition coefficient, Caco-2 cell permeability, serum protein binding, number of likely metabolic reactions and other 18 descriptors related to adsorption, distribution, metabolism and excretion (ADME properties) of the inhibitors were computed by the QikProp program[@CIT0034] based on the methods of Jorgensen[@CIT0035]. According to these methods, experimental results of more than 710 compounds including about 500 drugs and related heterocycles, were correlated with computed physico-chemical descriptors, resulting in an accurate prediction of molecule's pharmacokinetic profile. Drug likeness (\#stars) is represented by the number of descriptors that exceed the range of values determined for 95% of known drugs out of 24 selected descriptors computed by the QikProp[@CIT0034]. Drug-likeness was used as the global compound selection criterion related to ADME properties. The selected ADME descriptors were calculated from 3D structures of compounds considered. They were used to assess the pharmacokinetics profile of designed compounds and served also for the VL focusing.

2.8.. Virtual combinatory library generation {#s0010}
--------------------------------------------

The analogue model building was performed with Molecular Operating Environment (MOE) program[@CIT0038]. The library of analogues was enumerated by attaching R-groups (fragments, building blocks) onto HLCIC scaffold using the Quasar CombiDesign module of MOE[@CIT0038]. Reagents and chemicals considered in this paper were selected from the directories of chemicals available from the commercial sources. Each analogue was built as a neutral molecule in the MOE program[@CIT0038], its geometry was refined by MM optimisation through smart minimiser of DS 2.5[@CIT0030] meeting high convergence criteria (threshold on energy difference of 10^−4 ^kcal·mol^−1^ and root mean square deviation (RMSD) of 10^−5 ^Å), dielectric constant of 4, using class II consistent force field CFF[@CIT0039].

2.9.. ADME-based library focusing {#s0011}
---------------------------------

Twenty-four pharmacokinetics-related molecular descriptors available in QikProp[@CIT0034], which characterise a wide spectrum of molecular properties as described in [Section 2.7](#s0009){ref-type="sec"}, were used. Optimum ranges of these 24 descriptors were defined in terms of upper and lower bounds according to QikProp[@CIT0034]. Among them predicted drug-likeness (\#stars, [Section 2.7](#s0009){ref-type="sec"}) was used to retain drug-like HLCIC analogues in the focused VL.

2.10.. Pharmacophore-based library focusing {#s0012}
-------------------------------------------

The pharmacophore model (PH4) described in [Section 2.6](#s0008){ref-type="sec"} was derived from the bound conformations of HLCIC at the active site of FP-2. The enumerated and ADME-focused VL was further evaluated by using the pharmacophore mapping protocol available of DS 2.5[@CIT0030]. Within this protocol, each generated conformer of the analogues was geometry optimised by means of the CFF force field for a maximum of 500 energy minimisation steps and subsequently aligned and mapped to the PH4 model in order to select the top ranking overlaps. Twenty best-fitting inhibitor conformers were saved and clustered into 10 conformational families according to their mutual RMSD by Jarvis-Patrick complete linkage clustering method[@CIT0040]. The best representative of each cluster was considered for the virtual screening of analogues. Only those analogues mapping to all PH4 features were retained for the *in silico* screening.

2.11.. In silico screening {#s0013}
--------------------------

The conformer with the best match to the PH4 pharmacophore in each cluster of the focused library subset was selected for *in silico* screening by the complexation QSAR model. The relative GFE of E:I complex formation in water ΔΔ*G* ~com~ was computed for each selected new analogue and then used for prediction of FP-2 inhibitory potencies (*IC* ~50~ ^pre^) of the focused VL of HLCIC analogues by inserting this parameter into the target-specific scoring function. The scoring function, which is specific for the FP-2 receptor of *Pf* inhibition, is given in [Equation (2)](#M0002){ref-type="disp-formula"}, was parameterised using the QSAR model of training set of HLCIC inhibitors[@CIT0012]. $$pIC_{50}{}^{\text{pre}} = - {\,\text{log}\,}_{10}IC_{50}{}^{\text{pre}} = a \cdot \Delta\Delta G_{\text{com}} + b$$

3.. Results and discussion {#s0014}
==========================

A series of 18 \[15 training set HLCIC and 3 validation set (VS) HLCIV\] of HLCIC inhibitors and their experimental activities (*IC* ~50~ ^exp^) from the same laboratory[@CIT0012] were selected ([Table 1](#t0001){ref-type="table"}). These activities cover a relatively wide range 6.8 µM ≤ *IC* ~50~ ^exp^ ≤ 90 µM and allowed building of a valid QSAR model.

###### 

Training set (HLCIC) and validation set (HLCIV) of FP-2 inhibitors[@CIT0012] used in the preparation of QSAR model of inhibitor binding to the FP-2 of *Pf*.

  ![](IENZ_A_1564288_ILG0001_B.gif)Chalcone scaffold                                                         
  ---------------------------------------------------- -------- -------- -------- -------- -------- -------- -------------------
  HLCIC1                                               --OMe    --H      --OMe    H        lki      H        6.80
  HLCIC2                                               --H      --H      --OMe    H        lki      H        10.29
  HLCIC3                                               --OMe    --OMe    --OMe    H        lki      H        11.49
  HLCIC4                                               --H      --H      --OMe    lki      H        H        25.44
  HLCIC5                                               --OMe    --H      --OMe    lki      H        H        15.58
  HLCIC6                                               --OMe    --OMe    --OMe    lki      H        H        90.47
  HLCIC7                                               --H      --H      --OMe    H        H        lki      10.84
  HLCIC8                                               --OMe    --OMe    --OMe    H        H        lkl      28.50
  HLCIC9                                               --H      --H      --lki    H        H        --OMe    15.89
  HLCIC10                                              lki      --H      H        H        H        --OMe    15.96
  HLCIC11                                              lki      --H      H        --OMe    --H      --OMe    15.04
  HLCIC12                                              lki      H        H        --OMe    --OMe    --OMe    15.33
  HLCIC13                                              --H      lki      H        --H      --H      --OMe    9.91
  HLCIC14                                              --H      lki      H        --OMe    --H      --OMe    10.61
  HLCIC15                                              --H      lki      H        --H      --H      --OMe    16.73
  Validation set                                       *R*~1~   *R*~2~   *R*~3~   *R*~4~   *R*~5~   *R*~6~   *IC*~50~^exp^(μM)
  HLCICV1                                              --OMe    --OMe    --OMe    H        H        --lki    16.62
  HLCICV2                                              --H      --H      --lki    --OMe    --OMe    --OMe    25.06
  HLCICV3                                              --H      --H      --lki    --OMe    --H      --OMe    18.28

3.1.. Results {#s0015}
-------------

The relative GFE of E:I complex formation ΔΔ*G* ~com~ was calculated for the FP-2: HLCIC complexes as described in [Section 2](#s0002){ref-type="sec"}. [Table 2](#t0002){ref-type="table"} shows GFE and their components ([Equation (1)](#M0001){ref-type="disp-formula"}). The ΔΔ*G* ~com~ reflects the mutual affinity between the enzyme and the inhibitor. Since it is calculated via an approximate approach, the relevance of the binding model is evaluated by a linear regression with experimentally observed activity data (IC~50~ ^exp^)[@CIT0012] ([Equation (2)](#M0002){ref-type="disp-formula"}), which led to a linear correlation and QSAR model for the training set of HLCIC inhibitors. Two correlation equations obtained for the GFE of E:I complex formation ΔΔ*G* ~com~ (Equation (B)) and its enthalpic component ΔΔ*H* ~MM~ (Equation (A)), respectively are presented in [Table 3](#t0003){ref-type="table"} with the relevant statistical data plotted in [Figure 3](#F0003){ref-type="fig"}. The relatively high values of the regression coefficient *R* ^2^ and the Fischer *F*-test of the correlation involving ΔΔ*G* ~com~ indicate that there is a strong relationship between the binding model and the experimental inhibitory potencies of the HLCIC.

![(left): Plot of correlation between p*IC* ~50~ ^exp^ and relative enthalpic contribution to the GFE ΔΔ*H* ~MM~; (right) similar plot for relative complexation GFE ΔΔ*G* ~com~ of the training set of HLCIC, all in kcal·mol^−1^. Validation set data is shown in red colour.](IENZ_A_1564288_F0003_C){#F0003}

###### 

GFE of E:I complex formation (ΔΔ*G* ~com~ binding affinity) and its components for the training set of FP-2 inhibitors HLCIC1-15 and the validation set of inhibitors HLCIV1-3.

  Training set[^a^](#TF1){ref-type="table-fn"}   *M~w~*[^b^](#TF2){ref-type="table-fn"}   ΔΔ*H*~MM~[^c^](#TF3){ref-type="table-fn"}   ΔΔ*G*~sol~[^d^](#TF4){ref-type="table-fn"}   ΔΔ*TS*~vib~[^e^](#TF5){ref-type="table-fn"}   ΔΔ*G*~com~[^f^](#TF6){ref-type="table-fn"}   *IC*~50~^exp^ [^g^](#TF7){ref-type="table-fn"}
  ---------------------------------------------- ---------------------------------------- ------------------------------------------- -------------------------------------------- --------------------------------------------- -------------------------------------------- ----------------------------------------------------------------
  HLCIC1                                         607                                      0                                           0                                            0                                             0                                            6.80
  HLCIC2                                         577                                      1.66                                        −0.39                                        −1.37                                         2.64                                         10.29
  HLCIC3                                         637                                      13.38                                       −4.50                                        0.41                                          8.47                                         11.49
  HLCIC4                                         577                                      17.93                                       −3.63                                        0.24                                          14.06                                        25.44
  HLCIC5                                         607                                      15.96                                       −2.93                                        1.45                                          11.57                                        15.58
  HLCIC6                                         637                                      45.68                                       −3.75                                        −2.99                                         44.92                                        90.47
  HLCIC7                                         577                                      8.64                                        −3.59                                        0.45                                          4.60                                         10.84
  HLCIC8                                         570                                      26.70                                       5.21                                         8.22                                          23.69                                        28.5
  HLCIC9                                         577                                      12.61                                       −5.21                                        0.01                                          7.39                                         15.89
  HLCIC10                                        577                                      13.77                                       −6.83                                        −2.70                                         9.64                                         15.96
  HLCIC11                                        607                                      15.73                                       −5.84                                        −0.53                                         10.43                                        15.04
  HLCIC12                                        637                                      20.75                                       −5.80                                        0.41                                          14.54                                        15.33
  HLCIC13                                        577                                      4.80                                        −2.49                                        −3.03                                         5.34                                         9.91
  HLCIC14                                        607                                      6.81                                        −1.14                                        −1.87                                         7.55                                         10.61
  HLCIC15                                        637                                      19.63                                       −4.51                                        2.29                                          12.83                                        16.73
  Validation set                                 *M~w~*[^b^](#TF2){ref-type="table-fn"}   ΔΔ*H*~MM~[^c^](#TF3){ref-type="table-fn"}   ΔΔ*G*~sol~[^d^](#TF4){ref-type="table-fn"}   ΔΔ*TS*~vib~[^e^](#TF5){ref-type="table-fn"}   ΔΔ*G*~com~[^f^](#TF6){ref-type="table-fn"}   p*IC*~50~^pre^/p*IC*~50~^exp^ [^h^](#TF8){ref-type="table-fn"}
  HLCIV1                                         637                                      7.13                                        0.29                                         2.51                                          4.91                                         1.104
  HLCIV2                                         637                                      20.98                                       −4.83                                        1.14                                          15.01                                        1.079
  HLCIV3                                         607                                      16.47                                       −5.97                                        0.71                                          9.78                                         1.065

^a^For the chemical structures of the HLCIC see [Table 1](#t0001){ref-type="table"}.

^b^ *M~w~* is the molecular mass of the inhibitor (g·mol^−1^).

^c^ΔΔ*H* ~MM~ (kcal·mol^−1^) is the relative enthalpic contribution to the GFE change of the E:I complex formation derived by MM: ΔΔ*H* ~MM~ ≅ \[*E* ~tot~{FP-2:HLCICx} − *E* ~tot~{HLCICx}\] − \[*E* ~tot~{FP-2:HLCIC1} − *E* ~tot~{HLCIC1}\] where *E* ~tot~ is the MM total energy and HLCIC1 is the reference inhibitor.

^d^ΔΔ*G* ~sol~ (kcal·mol^−1^) is the relative solvation contribution to GFE change of the E:I complex formation ΔΔ*G* ~sol~ = \[*G* ~sol~{FP-2:HLCICx} − *G* ~sol~{HLCICx}\] − \[*G* ~sol~{FP-2:HLCIC1} − *G* ~sol~ {HLCIC1}\].

^e^ΔΔ*TS* ~vib~ (kcal·mol^−1^) is the relative entropic contribution of the inhibitor to the GFE related to protease-inhibitor complex formation: ΔΔ*TS* ~vib~ = \[*TS* ~vib~{FP-2:HLCICx} − *TS* ~vib~ {HLCICx}\] − \[*TS* ~vib~ {FP-2:HLCIC1} − *TS* ~vib~ {HLCIC1}\].

^f^ΔΔ*G* ~com~ (kcal·mol^−1^) is the relative GFE change of E:I complex formation: ΔΔ*G* ~com~ ≅ ΔΔ*H* ~MM~ + ΔΔ*G* ~sol~ − ΔΔ*TS* ~vib~.

^g^ *IC* ~50~ ^exp^ (μM) is the experimental half-maximal inhibitory concentration obtained from Ref. \[[@CIT0012]\].

^h^Ratio of predicted and experimental half-maximal inhibition concentrations p*IC* ~50~ ^pre^/p*IC* ~50~ ^exp^ (where p*IC* ~50~ ^pre^ = −log~10~ *IC* ~50~ ^pre^ was predicted from computed ΔΔ*G* ~com~ using the regression equation (B) shown in [Table 3](#t0003){ref-type="table"}.

###### 

Regression analysis of computed binding affinities ΔΔ*G* ~com~, its enthalpic component ΔΔ*H* ~MM~ and observed activity p*IC* ~50~ ^exp^ = −log~10~ *IC* ~50~ ^exp^ [@CIT0012] of hybrid lactone--chalcone and isatin--chalcone HLCIC.

  Statistical data of linear regression                                                \(A\)       \(B\)
  ------------------------------------------------------------------------------------ ----------- -------
  $pIC_{50}^{\text{exp}\,} = - 0.0224 \cdot \Delta\Delta H_{\text{MM}} + 5.1372$ (A)   --          --
  $pIC_{50}^{\text{exp}\,} = - 0.0236 \cdot \Delta\Delta G_{\text{com}} + 5.082$ (B)   --          --
  Number of compounds n                                                                15          15
  Squared correlation coefficient of regression *R*^2^                                 0.91        0.93
  LOO cross-validated squared correlation coef. *R*~xv~^2^                             0.90        0.92
  Standard error of regression *σ*                                                     0.08        0.07
  Statistical significance of regression, Fischer *F*-test                             139.1       180.4
  Level of statistical significance *α*                                                \>95%       \>95%
  Range of activities *IC*~50~^exp^ (µM)                                               6.8--90.0   

The bound conformation of the most potent FP-2 inhibitor HLCIC1[@CIT0012] in this QSAR model is displayed in [Figure 4](#F0004){ref-type="fig"} ([Table 1](#t0001){ref-type="table"}). The enzyme--inhibitor overall intermolecular interaction energy E~int~ in FP-2:HLClCx complexes is listed in [Table 4](#t0004){ref-type="table"} along with its correlation between that energy with observed inhibitory potency (*IC* ~50~ ^exp^) plotted in [Figure 5](#F0005){ref-type="fig"}. According to the statistical data in [Table 5](#t0005){ref-type="table"}, some 85% of the *IC* ~50~ ^exp^ variation is explained by E~int~ drop while moving from the best active HLClC1 to the less active one HLClC6. The quality of this correlation opens the gate to a deeper analysis of the intermolecular interaction energy E~int~ variation in light with structural requirement of FP-2 inhibition namely the active site pockets filling.

![(Top) 2D schematic interaction diagram of the most potent inhibitor HLCIC1 ([Table 1](#t0001){ref-type="table"}) at the active-site of FP-2 of *Pf*; (Middle, Bottom) 3D structure of the active-site with bound HLCIC1.](IENZ_A_1564288_F0004_C){#F0004}

![Plot of correlation between p*IC* ~50~ ^exp^ and overall intermolecular interaction energy *E* ~int~ in complexes FP-2:HLCIC~x~.](IENZ_A_1564288_F0005_B){#F0005}

###### 

Enzyme--inhibitor FP-2:HLCICx overall intermolecular interaction energy *E* ~int~ (kcal·mol^−1^).

  Training set[^a^](#TF9){ref-type="table-fn"}   E~vdw~[^b^](#TF10){ref-type="table-fn"}   E~ele~[^c^](#TF11){ref-type="table-fn"}   E~int~[^d^](#TF12){ref-type="table-fn"}   ΔE~int~   pIC~50~^exp^
  ---------------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- --------- --------------
  HLCIC1                                         −57.32                                    −2.07                                     −59.39                                    0         5.167
  HLCIC2                                         −54.43                                    −1.83                                     −56.26                                    3.13      4.987
  HLCIC3                                         −55.21                                    −1.53                                     −56.75                                    2.64      4.939
  HLCIC4                                         −48.41                                    0.09                                      −48.31                                    11.08     4.594
  HLCIC5                                         −49.63                                    −0.11                                     −49.75                                    9.64      4.807
  HLCIC6                                         −39.08                                    −1.76                                     −40.85                                    18.54     4.043
  HLCIC7                                         −53.71                                    −1.40                                     −55.11                                    4.28      4.964
  HLCIC8                                         −48.53                                    −3.35                                     −51.88                                    7.51      4.545
  HLCIC9                                         −52.19                                    0.32                                      −51.87                                    7.52      4.798
  HLCIC10                                        −48.93                                    −1.27                                     −50.21                                    9.18      4.796
  HLCIC11                                        −51.00                                    −1.62                                     −52.63                                    6.76      4.822
  HLCIC12                                        −52.05                                    −0.21                                     −52.26                                    7.13      4.814
  HLCIC13                                        −54.24                                    0.68                                      −53.55                                    5.84      5.003
  HLCIC14                                        −57.01                                    0.28                                      −56.73                                    2.66      4.974
  HLCIC15                                        −53.87                                    0.10                                      −53.76                                    5.63      4.776

^a^For the chemical structures of the training set of inhibitors see [Table 1](#t0001){ref-type="table"}.

^b^van der Walls component of non-bonded of interaction energy.

^c^Electrostatic component of non-bonded interaction energy.

^d^ *E* ~int~ is the interaction energy of two sets of atoms, one set represents residues of the FP-2 the other the inhibitor: *E* ~int~ = *E* ~vdW~ + *E* ~ele~.

^e^ *IC* ~50~ ^exp^ is the experimental half-maximal inhibitory concentration of the HLCIC obtained from reference[@CIT0012], p*IC* ~50~ ^exp^ = −log~10~(*IC* ~50~ ^exp^).

###### 

Regression analysis of computed interaction energies *E* ~int~ and observed activities p*IC* ~50~ ^exp^ of hybrid lactone--chalcone and isatin--chalcone HLCIC.

  Statistical data of linear regression                                               \(C\)
  ----------------------------------------------------------------------------------- -----------
  $pIC_{50}{}^{\,\text{exp}\,} = - 0.0548 \cdot \Delta E_{\text{int}} + 5.1734$ (C)    
  Number of compounds, n                                                              15
  Squared correlation coefficient of regression, *R*^2^                               0.85
  LOO cross-validated correlation coefficient, *R*~xv~^2^                             0.83
  Standard error of regression, σ                                                     0.106
  Statistical significance of regression, Fischer *F*-test                            72.10
  Level of statistical significance, α                                                \>95%
  Range of activities *IC*~50~^exp^ (μM)                                              6.8--90.0

The prominent role of the van der Waals (vdW) component of *E* ~int~ in the binding affinity of HLCIC to FP-2 of *Pf* is highlighted by the correlation between individual contributions to the overall *E* ~int~. In addition, to assess the impact of the residues occupying individual active site pockets (S1, S2, S3, and S1'; [Figure 4](#F0004){ref-type="fig"}) we have analyzed their contribution to the overall *E* ~int~ ([Table 6](#t0006){ref-type="table"}; [Figure 6](#F0006){ref-type="fig"}). The contribution of all the four pockets together explained 88% of the FP-2 inhibitory potencies of the training set inhibitors. This fell down to 31% when removing the contribution of the S2 pocket (67%). The filling of the S2 pocket by function groups of the inhibitors is therefore crucial for the FP-2:HLCIC1-15 affinity. Thus, our virtual FP-2 inhibitor design prioritised optimal filling of the S2 pocket by the HLCIC analogues.

![Plot of the correlation between interaction energies of residues belonging to individual active site pockets (S1, S2, S3, and S'1) and observed activities p*IC* ~50~ ^exp^.](IENZ_A_1564288_F0006_B){#F0006}

###### 

Active site residue contribution to *E* ~int~ in FP-2:HLCIC1 complex (kcal·mol^−1^).

  Pockets    pIC~50~^exp^   S1         S2                                                                                                               
  ---------- -------------- ---------- -------- -------- -------- -------- ------- -------- --------- --------- --------- --------- --------- --------- -------
  HLCIC 1    5.17           −1.5       −3.1     −0.7     0.5      −1.2     −3.8    −9.9     −3.7      −1.6      −1.9      −4.0      −2.3      −2.5      −16.0
  HLCIC 2    4.99           −0.9       −2.9     −2.9     0.5      −1.0     −3.8    −11.1    −3.7      −1.6      −1.9      −4.0      −2.3      −2.6      −16.1
  HLCIC 3    4.94           −1.9       −3.2     −0.9     −0.7     −1.1     −2.5    −10.4    −3.7      −2.1      −1.6      −3.5      −2.4      −0.3      −13.5
  HLCIC 4    4.59           −0.4       −0.8     −0.4     1.1      −0.3     −3.4    −4.1     −4.1      −1.4      −1.5      −2.7      −2.2      −2.0      −13.9
  HLCIC 5    4.81           −0.4       −0.9     −0.5     1.1      −0.3     −3.5    −4.5     −4.1      −1.4      −1.5      −2.8      −2.2      −1.9      −13.9
  HLCIC 6    4.04           −3.1       −3.2     −2.0     −2.6     −1.6     −5.6    −18.2    −0.2      −0.1      −0.1      −0.2      −0.7      −0.1      −1.3
  HLCIC 7    4.96           −1.4       −2.5     −0.7     0.4      −1.0     −3.9    −9.1     −3.7      −2.0      −1.8      −3.7      −2.2      −1.2      −14.7
  HLCIC 8    4.55           −0.8       −2.0     −0.7     −0.8     −0.9     −4.4    −9.6     −2.7      −1.6      −0.6      −0.3      −1.7      0.0       −6.8
  HLCIC 9    4.80           −1.3       −2.7     −1.1     0.8      −1.2     −4.0    −9.5     −3.7      −1.5      −1.6      −3.5      −1.7      −1.0      −13.1
  HLCIC 10   4.80           −0.5       −1.3     −1.1     0.4      −0.7     −5.2    −8.4     −2.5      −0.6      −1.0      −2.2      −1.4      −0.5      −8.2
  HLCIC 11   4.82           −0.3       −1.2     −0.9     −0.7     −0.7     −5.2    −9.0     −2.6      −0.7      −0.9      −2.4      −1.5      −0.6      −8.8
  HLCIC 12   4.81           −2.1       −3.9     −1.3     −0.7     −1.2     −3.0    −12.2    −3.3      −1.0      −0.9      −3.2      −1.5      −0.1      −9.9
  HLCIC 13   5.00           −0.7       −1.8     −0.8     0.1      −1.0     −5.8    −10.1    −3.7      −1.7      −2.1      −3.7      −1.7      −2.7      −15.7
  HLCIC 14   4.97           −1.2       −3.1     −1.0     0.1      −1.1     −5.1    −11.4    −3.7      −1.6      −2.0      −3.6      −1.8      −2.2      −14.9
  HLCIC 15   4.78           −0.9       −2.0     −0.6     1.6      −0.9     −3.9    −6.6     −3.8      −1.6      −2.2      −3.9      −1.9      −2.7      −16.1
  Pockets                   S3         S1'                                                                                                              
  Residue    pIC~50~^exp^   LYS + 76   ASN 77   TYR 78   GLY 82   GLY 83   Total   VAL150   VAL 152   ALA 157   ASN 173   HISD174   TRP 206   ASN 204   Total
  HLCIC 1    5.17           −0.4       −0.5     −8.3     −3.0     −3.8     −15.9   −0.5     0.0       0.0       −3.0      −4.6      −2.4      −0.1      −10.7
  HLCIC 2    4.99           −0.4       −0.5     −8.3     −2.9     −3.8     −15.8   −0.5     −0.2      0.0       −3.0      −4.2      −1.5      −0.1      −9.5
  HLCIC 3    4.94           −0.3       −0.3     −6.2     −2.3     −3.4     −12.6   −0.5     0.0       0.0       −3.6      −4.9      −1.7      −0.1      −10.8
  HLCIC 4    4.59           −0.3       −0.4     −7.1     −3.3     −4.0     −15.2   −0.5     0.0       0.0       −4.1      −4.3      −0.2      0.0       −9.2
  HLCIC 5    4.81           −0.3       −0.4     −7.2     −3.3     −4.0     −15.2   −0.5     0.0       0.0       −4.4      −4.8      −0.3      0.0       −10.1
  HLCIC 6    4.04           0.1        −0.1     −0.3     −2.0     −0.7     −3.0    −0.1     0.0       0.0       −4.2      −1.1      −2.4      0.0       −7.8
  HLCIC 7    4.96           −0.4       −0.5     −8.5     −2.8     −4.1     −16.3   −0.5     0.0       0.0       −2.7      −4.5      −0.6      0.0       −8.3
  HLCIC 8    4.55           −0.8       −3.2     −2.9     −4.6     −4.2     −15.5   −0.2     0.0       0.0       −2.1      −5.2      −0.7      0.0       −8.3
  HLCIC 9    4.80           −0.4       −0.4     −8.2     −3.0     −3.8     −15.9   −0.4     0.0       0.0       −2.7      −3.0      −0.4      0.0       −6.4
  HLCIC 10   4.80           −0.9       −0.8     −8.3     −5.7     −5.3     −21.0   −0.5     0.0       0.0       −3.4      −1.7      −0.1      0.0       −5.7
  HLCIC 11   4.82           −0.9       −0.8     −8.3     −6.1     −5.4     −21.5   −0.5     0.0       0.0       −3.8      −1.9      −0.1      0.0       −6.3
  HLCIC 12   4.81           −0.2       −0.4     −5.5     −3.9     −4.8     −14.8   −0.3     0.0       0.0       −2.9      −3.4      −0.6      0.0       −7.3
  HLCIC 13   5.00           −0.4       −0.5     −8.3     −3.0     −3.9     −16.1   −0.4     0.0       0.0       −2.6      −2.0      −0.4      0.0       −5.5
  HLCIC 14   4.97           −0.4       −0.5     −8.3     −3.2     −4.1     −16.4   −0.4     0.0       0.0       −2.7      −2.5      −1.4      0.0       −7.0
  HLCIC 15   4.78           −0.4       −0.5     −8.3     −3.1     −3.9     −16.1   −0.5     −0.1      −0.2      −4.2      −3.2      −0.5      −0.1      −8.9

The PH4 pharmacophore model of FP-2 inhibition elaborated from QSAR model and training set of HLCIC[@CIT0012] is presented in [Tables 7](#t0007){ref-type="table"} and [8](#t0008){ref-type="table"} and [Figure 7](#F0007){ref-type="fig"}. The 3D-QSAR PH4 generation was carried out in three steps: constructive, subtractive, and optimisation step ([Section 2](#s0002){ref-type="sec"}). During the constructive phase of HypoGen the most active HLCIC, for which *IC* ~50~ ^exp^ ≤ 2 × 6.8 µM, was selected as the leads. Thus, HLCIC1-3,7,13,14 (*IC* ~50~ ^exp^ ≤ 13.6 µM) were used to generate the starting PH4 features and those matching these leads were retained. During the subsequent subtractive phase, features which were present in more than half of the inactive HLCIC were removed. The PH4 models which contained all features were retained. None of the training set compounds was found to be inactive (*IC* ~50~ ^exp^\> 6.8 × 10^3.5^ = 21503.4 µM). During the final optimisation phase, the score of the PH4 hypotheses was improved. Hypotheses were scored via simulated annealing protocol according to errors in the activity estimates from the regression and complexity. At the end of optimisation, 10 best scoring unique hypotheses ([Table 7](#t0007){ref-type="table"}) displaying five features were kept. The reliability of the generated PH4 models was then assessed using the calculated cost parameters ranging from 74.8 (Hypo1) to 94.7 (Hypo10). Their statistical data (costs, root-mean-square deviation 2.056 ≤ *RMSD* ≤ 2.777 and 0.89 ≤ *R* ^2^ ≤ 0.94) are listed in [Table 7](#t0007){ref-type="table"}. The PH4 Hypo1, with the best *RMSD* and highest *R* ^2^ was retained for screening. Its regression equation p*IC* ~50~ ^exp^ = 0.9958·p*IC* ~50~ ^pre^ + 0.0192 ([Figure 7](#F0007){ref-type="fig"}; [Table 8](#t0008){ref-type="table"}), both *R* ^2^ and *R* ~xv~ ^2^ greater than 0.9 and *F*-test of 111.25 attest the predictive capacity of the PH4. The fixed cost of Hypo1 (74.8), lower than the null cost (296.7) by Δ = 221.9, is a chief indicator of the PH4 model predictability (Δ \> 70 corresponds to a probability higher than 90% that the model represents a valid correlation[@CIT0022]). The difference Δ ≥ 202 for the set of 10 hypotheses confirms the high quality of the PH4 model. The best-selected hypothesis Hypo1 represents a PH4 model with a similar level of predictive power as the QSAR model utilising the GFE of E:I complex formation with a probability of 98%.

![Distances (a), angles (b), features (c), and mapping (d) of the pharmacophore of the *Pf* FP-2 inhibition with the best training set inhibitor HLCIC1 (yellow)[@CIT0012]. The correlation plot of experimental vs. predicted inhibitory activity (e) is displayed. The features are coloured blue for hydrophobic aliphatic (HYd), green for hydrogen-bond (HB) acceptor (HBA), purple for HB donor (HBD) and orange for Aromatic (Ar). The arrows represent the projection of donor and acceptor features.](IENZ_A_1564288_F0007_C){#F0007}

###### 

Output parameters of 10 generated PH4 hypotheses for test set HLCIC FP-2 inhibitors[@CIT0012] after CatScramble validation procedure.

  Hypothesis   *RMSD*[^a^](#TF14){ref-type="table-fn"}   *R*^2^[^b^](#TF15){ref-type="table-fn"}   Total cost[^c^](#TF16){ref-type="table-fn"}
  ------------ ----------------------------------------- ----------------------------------------- ---------------------------------------------
  Hypo1        2.056                                     0.94                                      74.8
  Hypo2        2.368                                     0.92                                      80.7
  Hypo3        2.463                                     0.91                                      83.5
  Hypo4        2.3                                       0.92                                      84.5
  Hypo5        2.574                                     0.90                                      86.3
  Hypo6        2.614                                     0.90                                      88.4
  Hypo7        2.624                                     0.90                                      89.6
  Hypo8        2.738                                     0.89                                      91.8
  Hypo9        2.682                                     0.89                                      92.1
  Hypo10       2.777                                     0.89                                      94.7
  Fixed cost   0                                         1                                         30.9
  Null cost    6.142                                     0                                         296.7

^a^Root mean square deviation.

^b^Squared correlation coefficient.

^c^Overall cost parameter of the PH4.

###### 

Regression analysis of p*IC* ~50~ ^exp^ [@CIT0012] and computed p*IC* ~50~ ^pre^ of HLCIC towards the FP-2 of *Pf*.

  Statistical data of linear regression for Hypo 1 (D)                                             
  --------------------------------------------------------------------------------- ------------- ---
  $pIC_{50}{}^{\text{exp}\,} = 0.9958 \cdot pIC_{50}{}^{\text{pre}} + 0.0192$ (D)                  
  Number of compounds, n                                                            15             
  Squared correlation coefficient of regression, *R*^2^                             0.89           
  LOO cross-validation squared correlation coefficient, *R*~xv~^2^                  0.88           
  Standard error of regression, *σ*                                                 0.088          
  Statistical significance of regression, Fischer *F*-test                          111.249        
  Level of statistical significance, *α*                                            \>95%          
  Range of activities *IC*~50~^exp^ (μM)                                            \[6.8--90\]    

The substantial predictive power of the generated PH4 model was also checked through the computed ratio of PH4-predicted and experimentally observed activities (p*IC* ~50~ ^pre^/p*IC* ~50~ ^exp^) for the VS, ([Table 1](#t0001){ref-type="table"}). The computed ratios are as follows: HLCIV1:1.006, HLCIV2:1.057, HLCIV3:0.97; all of them close to one.

We have built a VL of new HLCIC analogues compounds with a variety of substitutions in ortho, meta, and para positions of the benzene rings with the goal to identify more potent orally bioavailable inhibitors of the FP-2 of *Pf*.

During the VL enumeration, the *R*-groups listed in [Table 9](#t0009){ref-type="table"} were attached to positions *R* ~1~--*R* ~6~ of the HLCIC scaffold to form a virtual combinatorial library of the size: R1 × R2 × R3 × R4 × R5 × R6 = 128 × 10 × 128 × 2 × 2 × 2 = 1,310,720 analogues for the scaffold SC1 ([Table 9](#t0009){ref-type="table"}) and R1 × R2 × R3 × R4 × R5 × R6 = 2 × 2 × 2 × 128 × 10 × 28 = 1,310,720 for SC2 ([Table 9](#t0009){ref-type="table"}) resulting together in 1,310,720 × 2 = 2,621,440 analogues. In order to match the substitution pattern of the best training set inhibitor HLCIC1 and taking into account the reported structural information about S pockets filling suitable for substitution[@CIT0012] not excluded through the Lipinski's rule violation (*M~w~* \> 500 g/mol)[@CIT0041], the VL underwent a focusing.

###### 

*R*-groups (fragments, building blocks, substituents) used in the design of the diversity VL of HLCIC analogues.

  ![](IENZ_A_1564288_ILG0004_B.gif)*R*~1~, *R*~2~, *R*~3~, *R*~4~, *R*~5~ and *R*~6~-groups ^a,b^   ![](IENZ_A_1564288_ILG0005_B.gif)linker-isatin (-lki)                                            
  ------------------------------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------- -----------------------------------------------
  1\. --F                                                                                           2\. --Cl                                                3\. --Br                                 4\. --I
  5\. --OH                                                                                          6\. --SH                                                7\. --NH~2~                              8\. --OCH~3~
  9\. --OCl                                                                                         10\. --OBr                                              11\. --OI                                12\. --OSH
  13\. --OCH~2~OH                                                                                   14\. --OCH~2~Cl                                         15\. --OCH~2~Br                          16\. --OCH~2~F
  17\. --OCH~2~I                                                                                    18\. --OCH~2~SH                                         19\. --OCH~2~NH~2~                       20\. --OCH~2~COO--
  21\. --OCH~2~COOH                                                                                 22\. --OCH~2~CHO                                        23\. --OCH~2~CN                          24\. --OCH~2~C(NH~2~)~2~^+^
  25\. --OCH~2~CONH~2~                                                                              26\. --OCH~2~NO~2~                                      27\. --OCH~2~SO~2~                       28\. --OCH~2~PO~3~H
  29\. --(CH~2~)~3~NH~2~                                                                            30\. --(CH~2~)~3~OH                                     31\. --(CH~2~)~3~Cl                      32\. --(CH~2~)~3~Br
  33\. --(CH~2~)~3~F                                                                                34\. --(CH~2~)~3~I                                      35\. --(CH~2~)~3~COO--                   36\. --(CH~2~)~3~COOH
  37\. --(CH~2~)~3~CHO                                                                              38\. --(CH~2~)~3~CN                                     39\. --(CH~2~)~3~C(NH~2~)~2~^+^          40\. --(CH~2~)~3~CONH~2~
  41\. --(CH~2~)~3~NH~2~CO                                                                          42\. --(CH~2~)~3~NO~2~                                  43\. --(CH~2~)~3~SO~2~H                  44\. --(CH~2~)~3~PO~3~H
  45\. cycloprop-2-enyl                                                                             46\. 2-hydroxycycloprop-2-en-1-yl                       47\. 2,3-dihydroxycycloprop-2-enyl       48\. 2-amino-3-hydroxycycloprop-2-enyl
  49\. 2,3-diaminocycloprop-2-enyl                                                                  50\. 2-amino-3-fluorocycloprop-2-enyl                   51\. 2,3-difluorocycloprop-2-enyl        52\. 2-chloro-3-fluorocycloprop-2-enyl
  53\. 2,3-dichlorocycloprop-2-enyl                                                                 54\. 2-chloro-3-mercaptocycloprop-2-enyl                55\. 2*H*-azirin-2-yl                    56\. 3*H*-diazirin-3-yl
  57\. 2*H*-triazirin-2-yl                                                                          58\. 1*H*-tetrazol-5-yl                                 59\. 1,4-dioxan-2-yl                     60\. --COO--
  61\. --COOH                                                                                       62\. --CHO                                              63\. --CN                                64\. --C(NH~2~)+
  65\. --CONH~2~^+^                                                                                 66\. --NCH~2~O                                          67\. --NO~2~                             68\. --SO~2~
  69\. --PO~3~H                                                                                     70\. --C~2~SO~2~H                                       80\. --HSO~2~                            81\. --CF~3~
  82\. --CCl~3~                                                                                     83\. --CH~2~CF~3~                                       84\. --CH~2~CCl~3~                       85\. --(CH~2~)~2~CCl~3~
  86\. --(CH~2~)~2~CF~3~                                                                            87\. --(CH~2~)~2~F                                      88\. --N = NH                            89\. --ON = NH
  90\. --ON = NOH                                                                                   91\. --N = NOH                                          92\. --NO                                93\. --CH = CH~2~
  94\. --CH~2~--CH = CH~2~                                                                          95\. --(CH~2~)4F                                        96\. --CH~2~--CH = C(NH~2~)~2~           97\. --CH~2~--CH = C(OH)NH~2~
  98\. --CH~2~--CH = C(OH)~2~                                                                       99\. --CH~2~--CH = CHOH                                 100\. --(CH~2~)~4~OH                     101\. --(CH~2~)~4~NH~2~
  102\. --CH~2~--CH = CH--CH~2~OH                                                                   103\. --CH~2~--CH = CH--CH~2~NH~2~                      104\. --CH~2~--CH = CH--CH~2~NCO         105\. --CH~2~--CH = CH--CH~2~NO~2~
  106\. --H~2~--CH = CH--CH~2~F                                                                     107\. --CH~2~--CH = CH--CH~2~COO--                      108\. --CH~2~--CH = CH--CH~2~COOH        109\. --CH~2~--CH = CH--CH~2~CO
  110\. --CH~2~--CH = CH--CH~2~CN                                                                   111\. --CH~2~--CH = CH--CH~2~C(NH~2~)~2~^+^             112\. --CH~2~--CH = CH--CH~2~CONH~2~     113\. --CH~2~--CH = CH--CH~2~SO~2~
  114\. --CH~2~--CH = CH--CH~2~--PO~3~                                                              115\. --CH = C(OH)~2~                                   116\. --CH~2~--CH = C(NH~2~)NO~2~^2−^    117\. --CH~2~--CH = C(NO~2~^2−^)~2~
  118\. --(CH~2~)~4~COOH                                                                            119\. --CH~2~--CH = CH--CH~2~--NH--CHO                  120\. --CH~2~--CH = CH--(CH~2~)~2~--CN   121\. 3-(2,3-difluorocycloprop-2-enyl) propyl
  122\. 3,4-difluorofuran-2-yl                                                                      123\. --(2-CN-6-MeO-1,2,5-triazin-4-yl)Me               124\. --(2-cyano-pyrimidin-4-yl)Me       125\. 2-cyano-pyrimidin-4-yl
  126\. (pyrimidin-4-yl)Me                                                                          127\. pyrimidin-4-yl                                    128\. (tetrahydro-2*H*-pyran)Me          129\. (piperidin-4-yl)Me
  130\. (isopropyl-piperidin-4-yl)Me                                                                131\. (tetrahydrofuran-2-yl) ethyl                      132\. --CH(Me)~2~                        133\. --CH~2~--CH(Me)--CH~3~
  134\. --CH~2~--CH(Me)--(CH~2~)~2~OH                                                               135\. --CH~2~--CH(Me)--(CH~2~)~2~NH~2~                  136\. --CH~2~--CH(Me)--(CH~2~)~2~Cl      137\. --CH(CH~2~)~2~--CH~3~ 138. --lki

^a^Fragments 1--128 were used in *R* ~1~-groups and *R* ~3~-groups; fragments 1--10 were used in *R* ~2~-group, fragments 138 and H for *R* ~4~, R~5~, and *R* ~6~ as scaffold SC1. Reversely fragments 1--128 were used in *R* ~6~-groups and *R* ~4~-groups; fragments 1--10 were used in *R* ~5~-group, fragments 138 and H for *R* ~3~, R~2~, and *R* ~1~ as scaffold SC2. Fragments 129--138 were used intuitively as *R* ~6~-groups substituents for the best VL hits at P2 position according to Schechter and Berger notation[@CIT0042].

^b^(--) bond indicates the attachment points of individual fragments.

To increase the content of drug-like and orally bioavailable analogues, the initial VL was filtered in an ADME-based focusing step. Only those molecules that satisfied the Lipinski's rule of five[@CIT0041] computed using QikProp[@CIT0016], were kept.

From the initial set of 2,621,440 (1,310,720 × 2) analogues, 18,288 (9144 × 2) fulfilled the Lipinski test (except the restriction *M~w~* \< 500 g/mol). Out of them, 141 analogues mapped to the 5 feature PH4 pharmacophore. The 81 best fitting analogues (PH4 hits) were retained and submitted to structure-based screening using the QSAR model and computed GFE of the FP-2:HLCIC complex formation. The calculated ΔΔ*G* ~com~ of the FP-2:HLCIC complexes of the hits, their components as well as predicted half-maximal inhibitory concentrations *IC* ~50~ ^pre^ estimated from the correlation equation (B) ([Table 3](#t0003){ref-type="table"}) are listed in [Table 10](#t0010){ref-type="table"}. Thirty-three others HLClC new analogues were added from an intuitive substitution approach intended to fill better the enzyme S2 pocket; they are listed in [Table 11](#t0011){ref-type="table"}. In the majority of new HLCIC analogues, the estimated inhibitory potencies are better than that for the most active training set inhibitor HLCIC1 (*IC* ~50~ ^exp^ = 6.8 µM)[@CIT0012].

###### 

GFE of FP-2:HLCIC complex formation and its components for the 81 virtually designed HLCIC exploring the pockets S1, S1', and S3.

  ----------------------------------- ----------------------- -------------------------------------------- --------------------------------------------- ---------------------------------------------- --------------------------------------------- ------------------------------------------------
  ![](IENZ_A_1564288_ILG0006_B.gif)                                                                                                                                                                                                                   
  No                                  Analogues               ΔΔ*H*~MM~[^a^](#TF19){ref-type="table-fn"}   ΔΔ*G*~sol~[^b^](#TF20){ref-type="table-fn"}   ΔΔ*TS*~vib~[^c^](#TF21){ref-type="table-fn"}   ΔΔ*G*~com~[^d^](#TF22){ref-type="table-fn"}   *IC*~50~^pre^[^e^](#TF23){ref-type="table-fn"}
  HLCIC1                              0                       0                                            0                                             0                                              6800[^f^](#TF24){ref-type="table-fn"}         
                                      Ortho 1 (o.SC1)                                                                                                                                                                                                 
                                                                                                                                                                                                                                                      
  1                                   33--5--4--lki--H--H     15.57                                        −1.88                                         1.08                                           12.59                                         16410
  2                                   31--2--30--lki--H--H    10.97                                        −1.13                                         −0.53                                          10.38                                         14550
  3                                   31--H--100--lki--H--H   10.46                                        −2.53                                         4.47                                           3.44                                          9980
  4                                   30--6--1--lki--H--H     12.32                                        −1.22                                         0.34                                           10.76                                         14850
  5                                   34--6--102--lki--H--H   9.70                                         −1.11                                         3.78                                           4.80                                          10740
                                                                                                                                                                                                                                                      
  No                                  Meta 1 (m.SC1)          ΔΔ*H*~MM~                                    ΔΔ*G*~sol~                                    ΔΔ*TS*~vib~                                    ΔΔ*G*~com~                                    *IC*~50~^pre^
                                                                                                                                                                                                                                                      
  6                                   51--1--1--H--lki--H     −67.28                                       1.49                                          −11.50                                         −54.29                                        430
  7                                   2--8--83--H--lki--H     −47.00                                       0.08                                          −4.35                                          −42.55                                        810
  8                                   45--1--99--H--lki--H    −44.27                                       0.76                                          −0.34                                          −43.14                                        790
  9                                   H--1--55--H--lki--H     −60.80                                       3.67                                          −10.46                                         −46.66                                        650
  10                                  H--H--5--H--lki--H      −44.12                                       −0.47                                         −4.68                                          −39.90                                        940
  11                                  4--5--1--H--lki--H      −45.96                                       −0.27                                         −6.09                                          −40.14                                        930
  12                                  33--H--102--H--lki--H   −49.75                                       0.57                                          1.00                                           −50.18                                        540
  13                                  33--1--99--H--lki--H    −49.55                                       0.76                                          −3.08                                          −45.69                                        690
  14                                  14--6--1--H--lki--H     −48.66                                       −0.27                                         −6.42                                          −42.51                                        820
  15                                  14--H--2--H--lki--H     −46.76                                       0.12                                          −5.41                                          −41.22                                        880
  16                                  33--1--37--H--lki--H    −47.22                                       2.17                                          −0.48                                          −44.56                                        730
  17                                  33--H--17--H--lki--H    −46.92                                       0.63                                          −0.52                                          −45.76                                        680
  18                                  12--H--52--H--lki--H    −39.45                                       1.21                                          −6.61                                          −31.61                                        1480
  19                                  31--1--63--H--lki--H    −53.54                                       −0.31                                         −3.02                                          −50.84                                        520
  20                                  31--7--4--H--lki--H     −49.53                                       −0.04                                         −2.20                                          −47.38                                        630
  21                                  29--2--106--H--lki--H   −45.44                                       1.56                                          1.92                                           −45.80                                        680
  22                                  12--1--106--H--lki--H   −47.88                                       0.37                                          −3.25                                          −44.25                                        740
  23                                  18--H--106--H--lki--H   −46.70                                       0.65                                          −1.26                                          −44.78                                        720
  24                                  16--1--106--H--lki--H   −49.96                                       0.07                                          −3.50                                          −46.38                                        660
  25                                  53--2--2--H--lki--H     −76.38                                       1.37                                          −13.87                                         −61.12                                        290
  26                                  122--1--1--H--lki--H    −95.43                                       1.53                                          −10.6                                          −83.3                                         90
  27                                  121--1--1--H--lki--H    −68.89                                       0.16                                          −9.19                                          −59.53                                        320
  28                                  53--H--2--H--lki--H     −75.66                                       0.92                                          −11.97                                         −62.76                                        270
  29                                  53--2--3--H--lki--H     −77.01                                       1.15                                          −13.81                                         −62.04                                        280
  30                                  124--1--1--H--lki--H    −66.93                                       −4.80                                         −2.48                                          −69.24                                        190
  31                                  125--1--1--H--lki--H    −100.28                                      −4.18                                         −1.85                                          −102.61                                       30
  32                                  126--1--1--H--lki--H    −71.57                                       −2.25                                         0.20                                           −74.03                                        150
  33                                  127--1--1--H--lki--H    −108.48                                      −0.47                                         −2.86                                          −106.09                                       30
                                                                                                                                                                                                                                                      
  No                                  Para 1 (p.SC1)          ΔΔ*H*~MM~                                    ΔΔ*G*~sol~                                    ΔΔ*TS*~vib~                                    ΔΔ*G*~com~                                    *IC*~50~^pre^
                                                                                                                                                                                                                                                      
  34                                  32--1--101--H--H--lki   −0.53                                        0.31                                          5.30                                           −5.51                                         6130
  35                                  31--2--62--H--H--lki    2.24                                         −0.80                                         0.12                                           1.31                                          8890
  36                                  52--H--101--H--H--lki   −0.57                                        0.05                                          −0.43                                          −0.08                                         8230
  37                                  53--1--29--H--H--lki    −4.13                                        1.19                                          −0.29                                          −2.64                                         7170
  38                                  4--8--31--H--H--lki     1.75                                         −0.12                                         −0.65                                          2.29                                          9370
                                      Ortho 2 (o.SC1)                                                                                                                                                                                                 
                                                                                                                                                                                                                                                      
  39                                  lki--H--H--33--4--29    −41.31                                       −3.01                                         1.85                                           −46.18                                        670
  40                                  lki--H--H--16--1--32    −42.10                                       −3.74                                         −2.16                                          −43.68                                        770
  41                                  lki--H--H--33--H--37    −40.09                                       −1.69                                         0.12                                           −41.90                                        840
  42                                  lki--H--H--15--H--1     −38.16                                       −3.96                                         −5.84                                          −36.28                                        1 150
  43                                  lki--H--H--9--1--93     −36.42                                       −5.15                                         −3.76                                          −37.81                                        1 060
  44                                  lki--H--H--29--H--2     −36.90                                       −2.59                                         0.49                                           −39.98                                        940
  45                                  lki--H--H--18--H--31    −41.11                                       −4.09                                         0.19                                           −45.40                                        700
  46                                  lki--H--H--33--H--38    −41.06                                       −2.68                                         −0.62                                          −43.12                                        790
  47                                  lki--H--H--53--H--30    −43.70                                       −4.14                                         −2.52                                          −45.33                                        700
  48                                  lki--H--H--4--6--93     −38.33                                       −2.03                                         −4.01                                          −36.34                                        1 140
  49                                  lki--H--H--2--5--31     −38.76                                       −4.17                                         −1.63                                          −41.30                                        870
  50                                  lki--H--H--4--7--32     −38.83                                       −5.59                                         −4.58                                          −39.84                                        940
  51                                  lki--H--H--4--6--38     −38.95                                       −3.98                                         −1.80                                          −41.13                                        880
  52                                  lki--H--H--1--6--H      −35.94                                       −4.94                                         −5.63                                          −35.25                                        1210
  53                                  lki--H--H--1--2--102    −39.53                                       −2.57                                         −0.92                                          −41.18                                        880
  54                                  lki--H--H--6--7--31     −37.56                                       −4.91                                         −1.72                                          −40.75                                        900
  55                                  lki--H--H--2--H--29     −37.12                                       −4.87                                         −2.10                                          −39.89                                        940
  56                                  lki--H--H--1--4--106    −53.16                                       −3.05                                         −6.37                                          −49.84                                        550
  ----------------------------------- ----------------------- -------------------------------------------- --------------------------------------------- ---------------------------------------------- --------------------------------------------- ------------------------------------------------

  No   Meta 2 (m.SC2)          ΔΔ*H*~MM~   ΔΔ*G*~sol~   ΔΔ*TS*~vib~   ΔΔ*G*~com~   *IC*~50~^pre^
  ---- ----------------------- ----------- ------------ ------------- ------------ ---------------
  57   H--lki--H--33--4--29    −45.50      −1.61        −0.12         −46.99       640
  58   H--lki--H--33--H--37    −46.73      −0.43        0.98          −48.15       600
  59   H--lki--H--15--H--1     −44.73      −1.07        −6.52         −39.28       970
  60   H--lki--H--29--H--2     −44.41      −1.59        0.32          −46.33       660
  61   H--lki--H--18--H--31    −43.73      −0.95        −3.32         −41.36       870
  62   H--lki--H--33--H--38    −45.55      −1.57        −0.28         −46.85       640
  63   H--lki--H--16--6--95    −47.00      −1.36        −1.35         −47.01       640
  64   H--lki--H--50--H--31    −45.63      0.42         −3.10         −42.10       830
  65   H--lki--H--H--1--46     −42.57      −1.87        −4.77         −39.67       950
  66   H--lki--H--H--7--31     −40.87      −2.81        −1.01         −42.66       810
  67   H--lki--H--51--H--30    −48.12      −2.20        0.68          −51.00       510
  68   H--lki--H--1--1--29     −39.50      −2.10        −1.34         −40.27       920
  69   H--lki--H--4--6--93     −42.95      −1.69        −3.28         −41.37       870
  70   H--lki--H--2--5--31     −41.22      −1.24        −2.76         −39.69       950
  71   H--lki--H--4--7--32     −42.49      −1.60        −4.56         −39.52       960
  72   H--lki--H--4--6--38     −42.63      −2.52        −4.73         −40.41       920
  73   H--lki--H--1--2--102    −42.14      −0.83        −3.42         −39.55       960
  74   H--lki--H--6--7--31     −41.44      −1.53        −2.26         −40.72       900
  75   H--lki--H--2--H--29     −42.23      −1.72        −3.29         −40.65       900
  76   H--lki--H--1--4--106    −44.34      −1.22        −5.99         −39.57       960
  No   Para 2 (p.SC2)          ΔΔ*H*~MM~   ΔΔ*G*~sol~   ΔΔ*TS*~vib~   ΔΔ*G*~com~   *IC*~50~^pre^
  77   H--H--lki--45--8--106   3.62        −0.94        −1.54         4.22         10410
  78   H--H--lki--52--H--1     0.38        −2.85        −4.56         2.09         9270
  79   H--H--lki--52--6--62    1.93        −1.28        −3.36         4.00         10290
  80   H--H--lki--4--8--4      0.29        −1.97        −6.02         4.33         10480
  81   H--H--lki--1--5--94     4.80        −1.67        1.31          1.81         9130

^a^ΔΔ*H* ~MM~ (kcal⋅mol^−1^) is the relative enthalpic contribution to the GFE change of FP-2:HLCIC complex formation ΔΔ*G* ~com~ (for details see footnote of [Table 2](#t0002){ref-type="table"}).

^b^ΔΔ*G* ~sol~ (kcal⋅mol^−1^) is the relative solvation GFE contribution to ΔΔ*G* ~com~.

^c^ΔΔ*TS* ~vib~ (kcal⋅mol^−1^) is the relative entropic (vibrational) contribution to ΔΔ*G* ~com~.

^d^ΔΔ*G* ~com~ (kcal⋅mol^−1^) the relative GFE change of the FP-2:HLCIC complex formation ΔΔ*G* ~com~ = ΔΔ*H* ~MM~ + ΔΔ*G* ~sol~ + ΔΔ*TS* ~vib~.

^e^ *IC* ~50~ ^pre^ (nM) is the predicted half-maximal inhibitory concentration of HLCIC towards FP-2 of *Pf* calculated from ΔΔ*G* ~com~ using correlation equation (B) ([Table 3](#t0003){ref-type="table"}).

^f^ *IC* ~50~ ^exp^ is given for the reference inhibitor HLCIC1[@CIT0012] instead of *IC* ~50~ ^pre^ (nM).

###### 

GFE of FP-2:HLCIC complex formation and its components for the 33 virtually designed HLCIC with intuitive P2 substitution (*R* ~6~-group) exploring the S2 pocket in addition to S1, S1', and S3.

  No    Analogues                 ΔΔ*H*~MM~   ΔΔ*G*~sol~   ΔΔ*TS*~vib~   ΔΔ*G*~com~   *IC*~50~^pre^
  ----- ------------------------- ----------- ------------ ------------- ------------ ---------------
  82    125--1--1--H--lki--128    −113.67     −2.72        2.83          −119.23      13
  83    125--1--1--H--lki--129    −111.20     −1.73        3.26          −116.20      15
  84    125--1--1--H--lki--134    −110.06     −1.39        1.87          −113.33      18
  85    126--1--1--H--lki--128    −84.96      0.07         3.59          −88.48       68
  86    126--1--1--H--lki--129    −84.46      0.97         3.18          −86.66       75
  87    126--1--1--H--lki--134    −79.04      0.83         3.95          −82.16       95
  88    127--1--1--H--lki--128    −119.71     2.17         1.45          −118.99      13
  89    127--1--1--H--lki--129    −117.15     2.79         2.60          −116.97      15
  90    127--1--1--H--lki--134    −113.51     2.86         3.15          −113.80      17
  91    53--2--2--H--lki--128     −76.09      1.53         −4.86         −69.70       187
  92    53--2--2--H--lki--129     −73.74      1.93         −2.96         −68.86       196
  93    122--1--1--H--lki--130    −107.89     0.72         −1.05         −106.12      26
  94    53--H--2--H--lki--128     −82.57      2.57         −1.77         −78.22       118
  95    53--H--2--H--lki--136     −72.35      2.61         −4.93         −64.81       245
  96    51--1--1--H--lki--128     −76.64      1.84         −2.59         −72.22       164
  97    51--1--1--H--lki--133     −68.35      1.15         −2.93         −64.27       252
  98    33--H--102--H--lki--131   −74.65      3.54         5.88          −77.00       126
  99    33--H--102--H--lki--134   −70.26      3.83         6.98          −73.41       153
  100   31--1--63--H--lki--128    −67.37      1.83         0.36          −65.91       230
  101   31--1--63--H--lki--129    −65.27      2.31         −0.70         −62.26       281
  102   51--H--30--H--lki--131    −80.47      −1.39        2.96          −84.82       82
  103   51--H--30--H--lki--136    −81.95      −0.23        4.15          −86.33       76
  104   31--H--100--lki--H--128   −73.53      0.58         9.39          −82.34       94
  105   31--H--100--lki--H--129   −65.73      0.96         9.24          −74.02       148
  106   31--H--100--lki--H--132   −67.83      2.41         1.39          −66.81       219
  107   1--4--106--lki--H--131    −70.26      2.91         −0.52         −66.84       219
  108   1--4--106--lki--H--133    −61.56      2.57         −0.44         −58.55       344
  109   125--1--1--H--lki--132    −108.80     −0.52        −4.86         −104.47      29
  110   125--1--1--H--lki--133    −110.12     −2.09        −0.96         −111.26      20
  111   125--1--1--H--lki--137    −114.41     −1.70        −0.29         −115.82      16
  112   127--1--1--H--lki--132    −113.82     3.33         −1.74         −108.76      23
  113   127--1--1--H--lki--133    −115.25     2.25         −1.23         −111.77      19
  114   127--1--1--H--lki--137    −120.03     2.59         −1.40         −116.04      15

In order to identify which substituents from [Table 9](#t0009){ref-type="table"} lead to new inhibitor candidates with high predicted potencies towards the FP-2, we have prepared histograms of the frequency of occurrence of the *R* ~1~ to *R* ~6~ groups in these 81 HLCIC virtual hits ([Figure 8](#F0008){ref-type="fig"}). Analysis of the histograms showed that the highest frequency of occurrence among the *R* ~1~-groups displayed the fragments 31, 33, and 53 ([Table 9](#t0009){ref-type="table"}). In case of *R* ~2~-groups fragments 1 and 2; for the *R* ~3~-groups fragments 1, 2, and 106; for the *R* ~4~-groups fragments 1, 2, 4, and 33 against 1 (4), 4 (4), 6 (7), and 7 (5) for R5 while the R6 group include chiefly fragments 1 (4), 29 (5), 31 (7), and 38 (4).

![Histograms of frequency of occurrence of individual *R* ~1~--*R* ~6~ groups in the 81 selected analogues mapping to the five-feature pharmacophore hypothesis Hypo1 (for fragments numbering see [Table 9](#t0009){ref-type="table"}).](IENZ_A_1564288_F0008_C){#F0008}

3.2.. Discussion {#s0016}
----------------

Training set of 15 HLCIC inhibitors and observed half-maximal inhibitory concentrations *IC* ~50~ ^exp^ [@CIT0012] were employed to derive QSAR model of FP-2 inhibition, which uses a single descriptor determined by molecular modelling (GFE of FP-2:HLCIC complex formation, ΔΔ*G* ~com~) and crystal structure of the FP-2 of *Pf* in complex with epoxysuccinate E64 (3BPF)[@CIT0015]. This statistically significant QSAR model confirmed the validity of our 3D models of HLCIC inhibitors and the mode of their binding to the active site of the FP-2 of *Pf*. Then a 3D pharmacophore (PH4) model of FP-2 inhibition was prepared for the bound conformations of HLCIC and was further used for screening of a large virtual combinatorial library of HLCIC analogues with the aim to identify more potent and bioavailable FP-2 inhibitors. The activities of the identified putative inhibitors and analogues proposed by structure-based design (*IC* ~50~ ^pre^) were predicted by linear QSAR regression equation (B) ([Table 3](#t0003){ref-type="table"}) and cross-checked by the PH4 regression equation (D) ([Table 8](#t0008){ref-type="table"}).

### 3.2.1.. QSAR model {#s0017}

The robustness of the single descriptor QSAR model was analyzed by assessing the role of the individual components of GFE of the FP-2:HLCIC complex formation ΔΔ*G* ~com~, namely the enthalpic, solvation and approximate entropic contributions. The relevance of the enthalpic contribution ΔΔ*H* ~MM~ to GFE was well confirmed by the quality of the regression (A) ([Table 3](#t0003){ref-type="table"}), indicating that a large part (91%) of the variation of the *IC* ~50~ ^exp^ can be explained by intermolecular interactions, which can be traced back to contributions of active site pockets (Sn) as well as individual residues, *E* ~int~ ([Table 6](#t0006){ref-type="table"}; [Figure 6](#F0006){ref-type="fig"}). Addition of the solvation term ΔΔ*G* ~sol~ maintained the relationship level between the experimental data and the modelling results. Finally, the validity of the model was increased by adding the ΔΔ*TS* ~vib~ term that describes the loss of the inhibitor vibrational entropy upon enzyme binding, which explained 93% of the variation of the *IC* ~50~ ^exp^. This last contribution is considered to be one of the most reliable indicators of the predictive power of QSAR models as reported by Freire et al.[@CIT0043]. The VS of 3 HLCICV inhibitors not included into the training set ([Table 2](#t0002){ref-type="table"}) confirmed good correlation between the ΔΔ*G* ~com~ and the observed activities *IC* ~50~ ^exp^ [@CIT0012] since the ratio between computed and experimental potencies p*IC* ~50~ ^pre^/p*IC* ~50~ ^exp^ was close to one. Therefore, the QSAR correlation equation (B) and computed relative GFE ΔΔ*G* ~com~ can be used for prediction of inhibitory potencies *IC* ~50~ ^pre^ of new HLCIC analogues against the FP-2 of *Pf*, since they share the same binding mode as the training set[@CIT0012].

### 3.2.2.. Binding mode of FP-2 inhibitors {#s0018}

Besides the robustness of the QSAR model, the analysis of the interactions between the HLCIC and active site residues revealed the key interactions responsible for the HLCIC affinity to FP-2, such as hydrogen bonds, van der Waals interactions, hydrophobic contacts, etc. As displayed in the 2D and 3D schemes of [Figure 4](#F0004){ref-type="fig"}, the binding of HLCIC1 to the active site of FP-2 is supported by the following interactions: HB with His174 and stacking interaction with Tyr78. To verify whether also other stronger interactions co-determine the binding mode of HLCIC to FP-2 active site and aid structure-based design of new analogues, interaction energies *E* ~int~ between active site residues and HLCIC were computed ([Table 6](#t0006){ref-type="table"}). The peptidyl structure of HLCIC shed some light on the structural features required for the binding affinity improvement, taking advantage of the S pockets filling ([Figure 6](#F0006){ref-type="fig"}). The computed overall interaction energy complexes FP-2:HLCICx correlated with the observed inhibitory potencies *IC* ~50~ ^exp^ of the training set HLCIC inhibitors ([Figure 5](#F0005){ref-type="fig"}; [Table 5](#t0005){ref-type="table"}). In particular, the correlation between the van der Waals component of *E* ~int~ and *IC* ~50~ ^exp^ pointed to the π--π stacking interaction involving the isatin moiety of the inhibitor and Tyr78.

The S2 pocket filling and interaction energy contribution shows dominant effect on the FP-2 inhibition as reported previously[@CIT0010]. On the other hand, comparison of the contributions to *E* ~int~ between the most active inhibitor HLCIC1 and less active one HLCIC6, corresponds to the trend of activities, but cannot explain the large gap in their inhibitory potencies (1224%). However, in a recent work, we succeeded in justifying the observed 37.5% jump in experimental biological activity between methylphosphonic arginine and hydroxamic acid derivative, both *Pf* Leucyl aminopeptidase (*Pf*A-M17) inhibitors by the enzyme active site residues contribution to *E* ~int~ at a level of 35%[@CIT0044]. Therefore, essential structural information needed for the design of novel potent HLCIC analogues was derived from a more predictive descriptor ΔΔ*G* ~com~. New inhibitor candidates were selected according to the workflow ([Figure 2](#F0002){ref-type="fig"}), by virtual screening from a diverse VL of analogues with the active site pockets filling as the central structural requirement displayed by the pharmacophore model of FP-2 inhibition provided by the one descriptor (GFE) QSAR model ([Table 3](#t0003){ref-type="table"}; [Figure 3](#F0003){ref-type="fig"}).

### *3.2.3. Analysis of new inhibitors from* in silico *screening* {#s0019}

An analysis of structural requirement for FP-2 inhibition at the level of hydrophobic contacts with the active site revealed that the P2 substituent, namely the *R* ~6~-group in the training set insufficiently explored the S2 pocket of the FP-2 active site. Therefore, new HLCIC analogues that match the FP-2 inhibition pharmacophore and fill better the S2 pocket may form potent FP-2 inhibitors ([Table 11](#t0011){ref-type="table"}).

The top scoring virtual hits are HLCIC analogues: 125--1--1--H--lki--H (*IC* ~50~ ^pre^ = 30 nM), 127--1--1--H--lki--H (*IC* ~50~ ^pre^ = 30 nM) without any specific P2 substitution; 125--1--1--H--lki--128 (*IC* ~50~ ^pre^ = 13 nM), 125--1--1--H--lki--129 (*IC* ~50~ ^pre^ = 15 nM), 127--1--1--H--lki--128 (*IC* ~50~ ^pre^ = 13 nM), 127--1--1--H--lki--129 (*IC* ~50~ ^pre^ = 15 nM), 125--1--1--H--lki--137 (*IC* ~50~ ^pre^ = 16 nM), and 127--1--1--H--lki--137 (*IC* ~50~ ^pre^ = 15 nM) with specific substitution targeting S2 pocket filling (*R* ~6~ substituent). While the first set displays predicted potency approximately 200 times better than the training set (HLCIC1; [Table 10](#t0010){ref-type="table"}), the last set of new analogues reached *IC* ~50~ ^pre^ 500 times better ([Table 11](#t0011){ref-type="table"}). Despite this exceedingly optimistic picture, our approach helped to identify interesting hydrophobic side chains (*R* ~6~-groups) such as (tetrahydro-2H-pyran)Me (128), (piperidin-4-yl)Me (129) and *n*-butane (137) for the S2 pocket filling with a bulkier group compared to the E64 which is decorated only with a short propyl chain at the P2 position. Indeed, from superimposition of the most active training set HLCIC ([Figure 9(a)](#F0009){ref-type="fig"}) and the less active ones ([Figure 9(b)](#F0009){ref-type="fig"}), we can see that E64 remains the only inhibitor to map the S2 pocket. The superimposition of the best-designed analogues ([Figure 10](#F0010){ref-type="fig"}) highlights the significance of hydrophobic contact with the S2 pocket. In fact, an additional pharmacophore derived from these new HLCIC analogues suggests an additional hydrophobic feature located at the S2 pocket ([Figure 11](#F0011){ref-type="fig"}). [Figure 12](#F0012){ref-type="fig"} shows the interactions of one of the best-designed analogues 125--1-1--H--lki-128 (*IC* ~50~ ^pre^ = 13 nM) with the FP-2 and the Connolly surface of the binding site shows the lipophilic S2 pocket accommodating a bulkier substituent contributing to better stabilisation and greater affinity. These results are in good agreement with the reported structural information from experimental structure--activity relationship on FP-2 and FP-3 pyrimidine-carbonitrile inhibitors[@CIT0045] as well as QSAR model and *in silico* design of dipeptide nitriles inhibitors of FP-3[@CIT0026] and FP-2[@CIT0046]. These conclusions are also in line with the recent SAR study on synthesis and molecular docking of coumarin containing pyrazoline derivatives as promising inhibitors of *in vitro* development of a chloroquine-sensitive (MRC-02) and chloroquine-resistant (RKL-2) strain of *Pf* [@CIT0047].

![(a) Superposition of most active training set HLClC inhibitors in bound conformation to crystallographic E64 (E64-RX: yellow; HLCIC1: green; HLCIC2: red; HLCIC7: violet; HLCIC13: blue; HLCIC14: orange). (b) Same superposition of less active training set HLClC (E64-RX: yellow; HLCIC4: white; HLCIC8: cyan; HLCIC6: brown).](IENZ_A_1564288_F0009_C){#F0009}

![Superimposition of the best analogues exploring the S2 pocket of FP-2 active site; 125--1-1-H-lki-128 (green, *IC* ~50~ ^pre^ = 13 nM), 125--1-1-H-lki-129 (red, *IC* ~50~ ^pre^ = 15 nM), 125--1-1-H-lki-134 (orange, *IC* ~50~ ^pre^ = 18 nM), 127--1-1-H-lki-128 (purple, *IC* ~50~ ^pre^ = 13 nM), 127--1-1-H-lki-129 (blue, *IC* ~50~ ^pre^ = 15 nM), 127--1-1-H-lki-134 (white, *IC* ~50~ ^pre^ = 15 nM).](IENZ_A_1564288_F0010_C){#F0010}

![The inhibition pharmacophore filling the S2 pocket of the FP-2 active site derived from the bound conformation of the best analogues with P2 substitution such as 125--1-1-H-lki-128 (*IC* ~50~ ^pre^=13 nM) (green): distances (a), angles (b), features (c), and 125--1-1-H-lki-128 mapping (d). Compared with the 3D QSAR complexation PH4, a supplementary hydrophobic feature corresponding to S2 pocket filling appeared. The features are coloured blue for hydrophobic aliphatic (HYd), green for hydrogen-bond acceptor (HBA), purple for hydrogen-bond donor (HBD) and orange for aromatic (Ar). The arrows represent the projection for the donor and acceptor features.](IENZ_A_1564288_F0011_C){#F0011}

![P2 substitution for the S2 pocket filling. (Left): Close up of 125--1-1--H--lki--128 (*IC* ~50~ ^pre^ = 13 nM) at the FP-2 active site. Carbon atoms of interacting residue side chains are coloured blue and those of ligand in green. (Right): Connolly surface of the FP-2 active site for 125--1-1--H--lki--128. The binding site surface is coloured according to residue hydrophobicity: red -- hydrophobic, blue -- hydrophilic and white -- intermediate.](IENZ_A_1564288_F0012_C){#F0012}

The ADME-related properties were also computed for the best active designed HLCIC as well as for drug used for the treatment of malaria ([Table 12](#t0012){ref-type="table"}). The chief descriptor, the number of stars (\*) deviation of the computed values from the optimum ranges for 95% of known drugs is close to those for known antimalarials. It can be noticed that the human oral absorption in gastrointestinal tract (HOA) is low for the new HLCIC analogues suggesting non-oral delivery. The blood--brain barrier descriptor is in the appropriate range.

###### 

Predicted ADME-related properties of the best designed HLCIC analogues and known antimalarial agents either in clinical use or currently undergoing clinical testing, as computed by QikProp[@CIT0034]

  No    Molecules[^a^](#TF25){ref-type="table-fn"}   \#stars[^b^](#TF26){ref-type="table-fn"}   MW \[g.mol^−1^\][^c^](#TF27){ref-type="table-fn"}   Smol \[A^2^\][^d^](#TF28){ref-type="table-fn"}   Smol, hfo[^e^](#TF29){ref-type="table-fn"} \[Å^2^\]   Vmol \[Å^3^\][^f^](#TF30){ref-type="table-fn"}   RotB[^g^](#TF31){ref-type="table-fn"}   HBdon[^h^](#TF32){ref-type="table-fn"}   HBacc[^i^](#TF33){ref-type="table-fn"}   logPo/w[^j^](#TF34){ref-type="table-fn"}   logSwat[^k^](#TF35){ref-type="table-fn"}   BIPcaco[^l^](#TF36){ref-type="table-fn"} \[nm.s^−1^\]   logB/B[^m^](#TF37){ref-type="table-fn"}   \#meta[^n^](#TF38){ref-type="table-fn"}   logKHSA[^o^](#TF39){ref-type="table-fn"}   HOA[^p^](#TF40){ref-type="table-fn"}   %HOA[^q^](#TF41){ref-type="table-fn"}   *IC*~50~^pred^[^r^](#TF42){ref-type="table-fn"} \[nM\]
  ----- -------------------------------------------- ------------------------------------------ --------------------------------------------------- ------------------------------------------------ ----------------------------------------------------- ------------------------------------------------ --------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------ -------------------------------------- --------------------------------------- --------------------------------------------------------
  31    125--1--1--H--lki--H                         7                                          686.0                                               1011                                             123.2                                                 1899                                             17                                      5                                        16                                       2.2                                        −6.1                                       2.2                                                     −3.6                                      4                                         −0.251                                     1                                      20.7                                    30
  33    127--1--1--H--lki--H                         5                                          661.0                                               989                                              128.4                                                 1834                                             16                                      5                                        15                                       2.8                                        −5.3                                       11.5                                                    −2.7                                      5                                         −0.196                                     1                                      36.6                                    30
  82    125--1--1--H--lki--128                       11                                         784,2                                               1135                                             371,1                                                 2266                                             19                                      5                                        18                                       4,1                                        −7,2                                       7,6                                                     −3,1                                      6                                         0,253                                      1                                      40.9                                    13
  83    125--1--1--H--lki--129                       12                                         783,2                                               1178                                             294,2                                                 2238                                             19                                      6                                        17                                       2,6                                        −6,7                                       0,2                                                     −4,2                                      5                                         0,104                                      1                                      0                                       15
  84    125--1--1--H--lki--134                       12                                         772.2                                               1230                                             303.4                                                 2290                                             22                                      6                                        18                                       3.0                                        −8.2                                       0.3                                                     −5.8                                      6                                         0.024                                      1                                      0                                       18
  88    127--1--1--H--lki--128                       8                                          759.2                                               1078                                             282.8                                                 2099                                             18                                      5                                        17                                       3.8                                        −5.8                                       16.2                                                    −2.6                                      7                                         0.068                                      1                                      45.1                                    13
  89    127--1--1--H--lki--129                       8                                          758.2                                               1114                                             291.2                                                 2130                                             18                                      6                                        16                                       3.2                                        −5.1                                       2.4                                                     −2.6                                      6                                         0.098                                      1                                      13.7                                    15
  90    127--1--1--H--lki--134                       8                                          747.1                                               1091                                             233.0                                                 2096                                             21                                      6                                        17                                       3.3                                        −5.4                                       5.3                                                     −3.5                                      7                                         −0.13                                      1                                      20.4                                    17
  93    122--1--1--H--lki--130                       10                                         824.3                                               1190                                             382.5                                                 2292                                             18                                      5                                        15                                       5.6                                        −7.3                                       7.5                                                     −1.9                                      6                                         0.80                                       1                                      36.3                                    26
  109   125--1--1--H--lki--132                       9                                          728.2                                               1082                                             258.3                                                 2040                                             18                                      5                                        16                                       3.2                                        −7.1                                       3.3                                                     −3.7                                      5                                         0.01                                       1                                      28.8                                    29
  110   125--1--1--H--lki--133                       10                                         742.2                                               1128                                             291.1                                                 2122                                             19                                      5                                        16                                       3.5                                        −7.7                                       2.3                                                     −4.1                                      5                                         0.15                                       1                                      27.9                                    20
  111   125--1--1--H--lki--137                       11                                         742.2                                               1141                                             310.9                                                 2138                                             20                                      5                                        16                                       3.6                                        −7.8                                       2.4                                                     −4.2                                      5                                         0.14                                       1                                      29.1                                    16
  112   127--1--1--H--lki--132                       5                                          703.1                                               1041                                             240.4                                                 1975                                             17                                      5                                        15                                       3.8                                        −6.0                                       19.1                                                    −2.5                                      6                                         0.10                                       1                                      46.3                                    23
  113   127--1--1--H--lki--133                       6                                          717.2                                               1072                                             270.3                                                 2040                                             18                                      5                                        15                                       4.2                                        −6.3                                       19.2                                                    −2.6                                      6                                         0.21                                       1                                      48.6                                    19
  114   127--1--1--H--lki--137                       6                                          717.2                                               1080                                             273.6                                                 2046                                             19                                      5                                        15                                       4.2                                        −6.3                                       17.5                                                    −2.7                                      6                                         0.17                                       1                                      47.8                                    15
        Amodiaquine                                  1                                          333.7                                               603                                              131.7                                                 1019                                             6                                       0                                        5                                        3.6                                        −4.8                                       1689                                                    −0.4                                      0                                         0.0                                        3                                      100.0                                    
        Arteether                                    1                                          312.4                                               531                                              506.0                                                 970                                              2                                       0                                        6                                        2.7                                        −3.1                                       5731.8                                                  0.2                                       0                                         −0.2                                       3                                      100.0                                    
        Artemether                                   1                                          298.4                                               491                                              465.5                                                 902                                              1                                       0                                        6                                        2.3                                        −2.9                                       5729                                                    0.3                                       0                                         −0.3                                       3                                      100.0                                    
        Artemisinin                                  0                                          282                                                 457                                              380.6                                                 848                                              0                                       0                                        5                                        1.7                                        −2.1                                       1886                                                    0.1                                       1                                         −0.3                                       3                                      95.8                                     
        Artésunate                                   0                                          384.4                                               644                                              465.1                                                 1156                                             4                                       1                                        8                                        2.5                                        −3.9                                       50.4                                                    −1.4                                      2                                         −0.1                                       3                                      72.0                                     
        Dihydroartémisinine                          1                                          284.4                                               477                                              395.7                                                 865                                              1                                       1                                        6                                        1.8                                        −2.8                                       1664.9                                                  −0.1                                      0                                         −0.1                                       3                                      95.4                                     
        Doxycycline                                  4                                          422.3                                               602                                              174.0                                                 1104                                             2                                       0                                        17                                       −4.0\*                                     −0.9                                       9.2\*                                                   −2.5                                      4                                         −2.9\*                                     1                                      20.8                                     
        Halofantrine                                 5                                          470.2                                               785                                              160.2                                                 1352                                             5                                       0                                        3                                        7.6\*                                      −8.5\*                                     2844.1                                                  0.2                                       0                                         1.5                                        1                                      100.0                                    
        Luméfantrine                                 5                                          496.7                                               819                                              160.7                                                 1438                                             7                                       0                                        3                                        8.3\*                                      −9.4\*                                     4337.2                                                  0.2                                       0                                         1.7\*                                      1                                      100.0                                    
        Méfloquine                                   2                                          362.2                                               533                                              0.0                                                   925                                              2                                       0                                        4                                        4.1                                        −5.9                                       2903.1                                                  0.5                                       0                                         0.1                                        3                                      100.0                                    
        Tétracycline                                 5                                          422.3                                               605                                              173.1                                                 1112                                             2                                       0                                        16                                       −3.4\*                                     −1.4                                       6.8\*                                                   −2.6                                      5                                         −2.5\*                                     1                                      21.8\*                                   

^a^Designed analogues ([Table 10](#t0010){ref-type="table"}).

^b^Drug likeness, number of property descriptors (from 24 out of the full list of 49 descriptors of QikProp, version 3.7, release 14) that fall outside of the range of values for 95% of known drugs.

^c^Molecular weight in g.mol^−1^ (range for 95% of drugs: 130--725 g.mol^−1^).

^d^Total solvent-accessible molecular surface, in Å^2^ (probe radius 1.4 Å) (range for 95% of drugs: 300--1000 Å^2^).

^e^Hydrophobic portion of the solvent-accessible molecular surface, in Å^2^ (probe radius 1.4 Å) (range for 95% of drugs: 0--750 Å^2^).

^f^Total volume of molecule enclosed by solvent-accessible molecular surface, in Å^3^ (probe radius 1.4 Å) (range for 95% of drugs: 500--2000 Å^3^).

^g^Number of non-trivial (not CX3), non-hindered (not alkene, amide, small ring) rotatable bonds (range for 95% of drugs: 0--15).

^h^Estimated number of hydrogen bonds that could be donated by the solute to water molecules in solution, averaged over a number of configurations (range for 95% of drugs: 0.0--6.0).

^i^Estimated number of hydrogen bonds that could be accepted by the solute from water molecules, averaged taken over a number of configurations (range for 95% of drugs: 2.0--20.0).

^j^Logarithm of partitioning coefficient between *n*-octanol and water phases (range for 95% of drugs: −2 to 6.5).

^k^Logarithm of predicted aqueous solubility, log S. S in mol⋅dm^−3^ is the concentration of the solute in a saturated solution that is in equilibrium with the crystalline solid (range for 95% of drugs: −6.0 to 0.5).

^l^Predicted apparent Caco-2 cell membrane permeability in Boehringer-Ingelheim scale, in \[nm⋅s ^−1^\] (range for 95% of drugs: \<25 poor, \>500 great).

^m^Logarithm of predicted brain/blood partition coefficient. (range for 95% of drugs: −3.0 to 1.2).

^n^Number of likely metabolic reactions (range for 95% of drugs: 1--8).

^o^Logarithm of predicted binding constant to human serum albumin (range for 95% of drugs: −1.5 to 1.5).

^p^Human oral absorption (1: low; 2: medium; 3: high).

^q^Percentage of human oral absorption in gastrointestinal tract (\<25% poor, \>80% high).

^r^Predicted inhibition constants *IC* ~50~ ^pre^. *IC* ~50~ ^pre^ was predicted from computed ΔΔ*G* ~com~ using the regression equation shown in [Table 3](#t0003){ref-type="table"}.

\*Asterisk indicates that the property descriptor value falls outside the range of values for 95% of known drugs.

4.. Conclusion {#s0020}
==============

Natural-product-like hybrids design for *pf*FP-2 inhibition stems from the multiple need to provide naturally occurring, resistance overcoming, and favourable pharmacokinetic profile compounds mimicking in this way, how nature synthesise by exploring efficiently chemical space. HLCIC antimalarials structural requirement for falcipain 2 inhibition has been assessed from the complexation "one descriptor" QSAR correlating GFE upon *pf*FP-2:HLCIC complex formation with activity. Moreover the derived 3D QSAR Pharmacophore was augmented to S2 pocket filling in order to provide a complete PH4 able to guide synthesis of novel potent isatin--chalcone inhibitors. Virtual screening of large and diverse VL of HLCIC analogues by the PH4 led to identification of 125--1--1--H--lki--H (30 nM), 127--1--1--H--lki--H (30 nM) 125--1--1--H--lki--128 (13 nM), 125--1--1--H--lki--129 (15 nM), 127--1--1--H--lki--128 (13 nM), 127--1--1--H--lki--129 (15 nM), 125--1--1--H--lki--137 (16 nM) and 127--1--1--H--lki--137 (15 nM); the best ones according to our design strategy based on S2 hydrophobic contact display predicted potency reaching 200 times that of the most active training set HLCIC1. They are recommended for synthesis and evaluation to check the efficiency of our design approach and guide future discovery of non-peptide, natural product like hybrids FP-2 inhibitors.
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